Triple Incretin Receptor Agonist | GLP-1 + GIP + Glucagon for Advanced Fat Loss & Metabolic Optimization
Overview:
Retatrutide is a next-generation triple incretin agonist, targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and Glucagon receptors simultaneously. This unique triple-action mechanism offers a powerful blend of appetite suppression, fat oxidation, and energy regulation, positioning Retatrutide at the forefront of advanced weight management and metabolic enhancement therapies.
This product is supplied as a lyophilized powder and requires reconstitution before use.
